<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>SE-0-SE-6-6105013701-GGG-12250</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">ReAct 2015-2018</narrative>
   <narrative xml:lang="SV">ReAct 2015-2018</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">Continued core support to the network ReAct working to advocate for   improved antiobiotic resistance preparedness globally with particular focus on Africa, Asia and Latinamerica.</narrative>
   <narrative xml:lang="SV">Syftet med ReAct:s verksamhet &#xE4;r att driva och lyfta fr&#xE5;gan om antibiotikaresistens samt behovet av framtagandet av nya l&#xE4;kemedel. ReAct st&#xF6;djer ett flertal andra organisationer genom att mobilisera st&#xF6;d f&#xF6;r och direkt belysa fr&#xE5;gan om antibiotikaresistens. St&#xF6;d ges &#xE4;ven till flera l&#xE4;nder i Afrika, Latinamerika och Sydostasien i framtagandet av nationella policyer och ramverk f&#xF6;r rationell anv&#xE4;ndning av antibiotika. 

Antibiotikaresistens har med begr&#xE4;nsad framg&#xE5;ng, diskuterats och hanterats p&#xE5; den globala h&#xE4;lsoarenan, trots de omfattande och allvarliga konsekvenserna. P&#xE5; senare &#xE5;r m&#xE4;rks dock en viktig politisk sv&#xE4;ngning och fr&#xE5;gan har mer systematiskt och strategiskt uppm&#xE4;rksammats genom flera olika initiativ och sammanhang, inte minst genom samarbetet med WHO. Sverige (genom olika departement och myndigheter) och ReAct har i denna kontext varit viktiga akt&#xF6;rer som gemensamt bedrivit ett framg&#xE5;ngsrikt opinionsarbete.

Vid sidan om WHO &#xE4;r ReAct den enda organisation som bem&#xF6;ter fr&#xE5;gan om antibiotikaresistens fr&#xE5;n ett globalt och multisektoriellt perspektiv med fokus p&#xE5; l&#xE5;g-och medelinkomstl&#xE4;nder. M&#xE5;nga omr&#xE5;den som har varit f&#xF6;rem&#xE5;l f&#xF6;r ReAct:s l&#xE5;ngsiktiga arbete har mognat och flera konkreta steg mot implementering av strategier tas just nu. Detta g&#xE4;ller inte minst WHO:s globala handlingsplan mot antibiotikaresistens. Det p&#xE5;g&#xE5;r &#xE4;ven diskussioner om ett globalt offentligt-privat partnerskap f&#xF6;r att utveckla nya antibiotika och det f&#xF6;rs samtal mellan ReAct, Dag Hammarskj&#xF6;ldfonden och UD om m&#xF6;jligheterna att etablera ett internationellt juridiskt ramverk i fr&#xE5;gan. ReAct samverkar dessutom med UD vad g&#xE4;ller m&#xF6;jligheterna att inkludera antibiotikaresistens i de nya utvecklingsm&#xE5;len.

ReAct &#xE4;r ingen sedvanlig och frist&#xE5;ende organisation utan snarare ett n&#xE4;tverk, inhyst av Uppsala universitet, Sidas juridiska part. F&#xF6;rutom Uppsala universitet &#xE4;r ReAct &#xE4;ven inhyst av tv&#xE5; ytterligare universitet (i Malaysia och USA) och tv&#xE5; organisationer (i Guatemala och Kenya). Uppsala universitet har ing&#xE5;tt avtal med dessa fyra universitet och organisationer (noder) som i sin tur ocks&#xE5; har ing&#xE5;tt avtal med andra organisationer (antal skiljer sig fr&#xE5;n node till node). 

Sida har st&#xF6;ttat ReAct sedan dess grundande 2005 och har varit den enda kontinuerliga finansi&#xE4;ren, vilket Sida anser vara problematiskt. ReAct skulle inte kunna bedriva sin verksamhet utan st&#xF6;d fr&#xE5;n Sida. Trots anstr&#xE4;ngningar har ReAct inte lyckats s&#xE4;kra annan finansiering med undantag av begr&#xE4;nsat st&#xF6;d till specifika aktiviteter.      

Insatsen bed&#xF6;ms som medelrisk till f&#xF6;ljd av att ReAct (Uppsala universitet - UU) inte anv&#xE4;nder sig av n&#xE5;gon formell urvalsprocess avseende valet av partners eller en formell bed&#xF6;mning av deras kapacitet. Partners v&#xE4;ljs utifr&#xE5;n kunskap hos ReAct:s personal; deras personliga kunskap om och erfarenhet av att arbeta med vissa organisationer och personer (avseende b&#xE5;de noderna och nodernas partners). De avtal som undertecknades reglerar partnerskapet mellan UU och noderna och t&#xE4;cker m&#xE5;nga viktiga omr&#xE5;den. Varje node har i sin tur olika avtal med sina partners som inte regleras/som &#xE4;r helt oberoende av UU (Sida:s avtalspartner). Genom fortsatt dialog och rapportering, f&#xF6;rv&#xE4;ntas det att Sida (men &#xE4;ven UU) kommer att f&#xE5; st&#xF6;rre klarhet i hur samarbetet framf&#xF6;rallt hanteras mellan noderna och deras partners (inklusive hur eventuella brister hanteras). 

Ingen dokumentation har dock identifierats som skulle kunna peka p&#xE5; eventuell/n&#xE5;gon form av missk&#xF6;tsel eller bristande f&#xF6;rm&#xE5;ga att genomf&#xF6;ra planerade aktiviteter. Troligtvis finns det ett behov av att st&#xE4;rka omr&#xE5;den s&#xE5; som finansiell hantering samt uppf&#xF6;ljning och utv&#xE4;rdering (s&#xE5; som ReAct har sj&#xE4;lv p&#xE5;pekat). 

Sida har beslutat att ReAct ska genomg&#xE5; en ISK-granskning under 2015 (i enlighet med beslut om konsultinsatser nr 2014-000911). ISK-granskning kommer att p&#xE5;b&#xF6;rjas s&#xE5; snart som m&#xF6;jligt under 2015 och kommer att t&#xE4;cka samtliga viktiga riskomr&#xE5;den. I avtalet tydligg&#xF6;rs att den andra utbetalningen (och f&#xF6;ljande) &#xE4;r avh&#xE4;ngig ReAct:s implementering av eventuella ISK-rekommendationer. 

Sida kan komma att beh&#xF6;va omv&#xE4;rdera sin bed&#xF6;mning av ReAct mot bakgrund av ISK-resultaten. Dessutom kommer en utv&#xE4;rdering att genomf&#xF6;ras under 2016, den senaste utv&#xE4;rderingen genomf&#xF6;rdes under 2010. ISK-granskningen och utv&#xE4;rderingen kommer att visa p&#xE5; huruvida det finns n&#xE5;got behov av att ompr&#xF6;va den gjorda riskbed&#xF6;mningen och/eller ytterligare dialogomr&#xE5;den.

Sida bed&#xF6;mer att den inkomna reviderade budgeten och arbetsplanen &#xE4;r b&#xE5;da rimliga och inneh&#xE5;ller information som kr&#xE4;vs f&#xF6;r utbetalning av medel. Budgeten redog&#xF6;r t.ex. tydligare de olika budgetposterna s&#xE5;som l&#xF6;ner, m&#xF6;ten, resor och andra direkta och indirekta kostnader.</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">ReAct articulates its mission as a world free of fears related to untreatable infections. This mission will be achieved by addressing the issue of antibiotic resistance (ABR) and retaining the effectiveness of existing as well as promoting the development of new antibiotics. Therefore, the overall objective of ReAct is to: contribute to the development and promotion of equitable and ecologically grounded solutions to contain ABR, through: advocacy, partnerships building as well as functioning as an easily accessible center of excellence for the management and dissemination of information and analysis on ABR. This is expected to contribute towards the attainment of universal health coverage as well as poverty reduction.</narrative>
  </description>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-6" role="3" type="10">
   <narrative xml:lang="EN">Swedish International Development Cooperation Agency</narrative>
  </participating-org>
  <participating-org ref="51000" role="2">
   <narrative xml:lang="EN">Uppsala universitet</narrative>
  </participating-org>
  <participating-org ref="51000" role="4" type="80">
   <narrative xml:lang="EN">Uppsala universitet</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2015-04-01" type="1"></activity-date>
  <activity-date iso-date="2015-04-01" type="2"></activity-date>
  <activity-date iso-date="2019-09-30" type="3"></activity-date>
  <activity-date iso-date="2019-09-30" type="4"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">Swedish International Development Cooperation Agency</narrative>
   </organisation>
   <telephone>+46 8 698 50 00</telephone>
   <email>sida@sida.se</email>
   <website>www.sida.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Valhallav&#xE4;gen 199, 105 25 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-region code="998" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Developing countries, unspecified</narrative>
  </recipient-region>
  <sector code="122" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Basic Health</narrative>
  </sector>
  <sector code="12250" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Infectious disease control</narrative>
  </sector>
  <policy-marker code="5" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="1" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="1" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="1" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="1" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="3"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="B01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget>
   <period-start iso-date="2015-01-01"></period-start>
   <period-end iso-date="2015-12-28"></period-end>
   <value currency="USD" value-date="2015-01-01">2758236.1524681766</value>
  </budget>
  <budget>
   <period-start iso-date="2016-01-01"></period-start>
   <period-end iso-date="2016-12-28"></period-end>
   <value currency="USD" value-date="2016-01-01">584351.0781277391</value>
  </budget>
  <budget>
   <period-start iso-date="2017-01-01"></period-start>
   <period-end iso-date="2017-12-28"></period-end>
   <value currency="USD" value-date="2017-01-01">1755001.755001755</value>
  </budget>
  <budget>
   <period-start iso-date="2018-01-01"></period-start>
   <period-end iso-date="2018-12-28"></period-end>
   <value currency="USD" value-date="2018-01-01">0</value>
  </budget>
  <budget>
   <period-start iso-date="2019-01-01"></period-start>
   <period-end iso-date="2019-12-28"></period-end>
   <value currency="USD" value-date="2019-01-01">0</value>
  </budget>
  <planned-disbursement>
   <period-start iso-date="2015-01-01"></period-start>
   <period-end iso-date="2015-12-28"></period-end>
   <value currency="USD" value-date="2015-01-01">2758236.1524681766</value>
  </planned-disbursement>
  <planned-disbursement>
   <period-start iso-date="2016-01-01"></period-start>
   <period-end iso-date="2016-12-28"></period-end>
   <value currency="USD" value-date="2016-01-01">584351.0781277391</value>
  </planned-disbursement>
  <planned-disbursement>
   <period-start iso-date="2017-01-01"></period-start>
   <period-end iso-date="2017-12-28"></period-end>
   <value currency="USD" value-date="2017-01-01">1755001.755001755</value>
  </planned-disbursement>
  <planned-disbursement>
   <period-start iso-date="2018-01-01"></period-start>
   <period-end iso-date="2018-12-28"></period-end>
   <value currency="USD" value-date="2018-01-01">-2e-10</value>
  </planned-disbursement>
  <planned-disbursement>
   <period-start iso-date="2019-01-01"></period-start>
   <period-end iso-date="2019-12-28"></period-end>
   <value currency="USD" value-date="2019-01-01">0</value>
  </planned-disbursement>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2015-04-01"></transaction-date>
   <value currency="USD" value-date="2015-04-01">5130912.412655</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2015-06-28"></transaction-date>
   <value currency="USD" value-date="2015-06-28">830436.6910656876</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2015-12-28"></transaction-date>
   <value currency="USD" value-date="2015-12-28">1927799.461402489</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-07-28"></transaction-date>
   <value currency="USD" value-date="2016-07-28">584351.0781277391</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-06-28"></transaction-date>
   <value currency="USD" value-date="2017-06-28">1755001.755001755</value>
  </transaction>
  <result aggregation-status="0" type="2">
   <title>
    <narrative xml:lang="EN">Results achieved</narrative>
    <narrative xml:lang="SV">Uppn&#xE5;dda resultat</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">During 2015-2018, ReAct has been a driving force behind many of the key advances in the field of antibiotic resistance (ABR). ReAct played a key role in lifting ABR and addressing low- and middle-income countries&#x2019; (LMICs) concerns to the global policy making processes, both on the road to the UN General Assembly (UNGA), the 2030 Agenda for Sustainable Development, and subsequently in the UN Interagency Coordination Group (IACG) on Antimicrobial Resistance (AMR). Strategic engagement and advocacy towards UN political process included speaking at the first UN briefing on &#x201C;Antimicrobial Resistance: An Emerging Global Threat&#x201D; for member states and intergovernmental agencies in June 2015, and co-organizing &#x201C;Meeting&#xA0;the Multisectoral Challenge of AMR&#x201D; in New York in June 2016 for country missions, UN agencies and other stakeholders in advance of negotiations around the UNGA High-Level Meeting on AMR.
&#xA0;
ReAct also championed the concept of delinkage for the development of new antibiotics which was included in the UN Political Declaration on AMR adopted at the UNGA in 2016.
&#xA0;
ReAct has increased its support - both on the ground and through an online technical resource repository, the ReAct Toolbox &#x2013; to governments for the development and implementation of their national action plans (NAPs), in India, El Salvador, Ecuador, and a number of countries across sub- Saharan Africa. ReAct has been actively engaged in NAP progress in Zimbabwe, Kenya, Zambia, Nigeria, Tanzania and Uganda where we offered instrumental support on national AMR situation analyses; developing, reviewing and publishing of AMR NAP documents; developing national antimicrobial stewardship (AMS) policies and frameworks and developing terms of reference documents for members of AMS committees in healthcare facilities.
&#xA0;
During the agreement phase ReAct &#xA0;has worked to raise and increase awareness of ABR at global, regional and community levels and has been instrumental in highlighting the One Health nature of ABR through various communication formats and channels. This includes ReAct&#x2019;s &#xA0;regional activities especially during the World Antibiotic Awareness Week (WAAW), and their increased online presence via a redesigned website, newsletter and social media, which has led to large increases in visits and engagements. In the domain of antibiotic use in agriculture and food production, ReAct&#x2019;s work in the consumer space culminated in the meeting &#x201C;Globalizing Food Campaigns: Sharing Strategies&#xA0;to Address Antimicrobial Resistance&#x201D; in Bangkok, in December 2018. This meeting was attended by more than 40 civil society representatives from across the world and has resulted in the &#x201C;Bangkok&#xA0;Declaration on Antimicrobial Resistance, Food Systems and Farming&#x201D; outlining the strategies which can incentivize reduction in antibiotic use in food animal production, while ensuring that principles of equity and sustainability are followed.
ReAct has also led coordination and communication activities engaging inter-sectoral partners, including the convening of the Antibiotic Resistance Coalition (ARC) and creating a network of regional and national ABR champions, that have become key voices of civil society and LMICs in the global policy debates on ABR. As demonstrated by the independent submissions by ARC members and partner organizations during the public consultation period for the IACG&#x2019;s draft recommendations in 2018, ReAct&#x2019;s work through ARC has effectively enabled other organizations to integrate work on ABR on their agenda. The Tripartite agencies (WHO, FAO and OIE) turned to ARC to host a global consultation for civil society on the Global Development and Stewardship Framework on Antimicrobial Resistance. In concert with partners, ReAct&#x2019;s ability to generate opportunities and processes for new and existing movements to influence discussions at the national and international level increases.
&#xA0;
During this grant period, ReActs newest node, ReAct Africa, has become established and a key player in the region. A network of &#x2018;champions&#x2019; has been created; together with ReAct Africa staff, individuals and organizations that are passionate about and engaged in the ABR issue have participated in a range of activities including the establishment of antimicrobial stewardship programs in Zambia, Nigeria and Kenya.&#xA0;Within 3 years, the ReAct Africa Conference has grown from 10 to over 20 countries in participation, coming from the human health, animal health, agriculture and environment sector. The conference has created a platform for exchange, cross-learning and provides south to south exchanges. The conference also plays a major role in building capacity on AMR for key stakeholders from various countries. It has been a &#x2018;training school&#x2019; on ABR/AMR and ReAct&#x2019;s Toolbox has provided great resources for countries to use.
ReAct has introduced, promoted, seed-funded and developed a range of innovative at community, school, hospital and policy levels. In collaboration with its partners around the world, ReAct has worked to share, adapt, evaluate and extend best practices to other locales, through the development of related materials, organization of study visits and various formats of seminars, workshops and trainings. As an example, the Alforja Educativa is an innovative ReAct initiative focused on educating children and teachers and utilizing schools as actors in awareness raising and social mobilization on ABR. Over the past few years, the Alforja has grown beyond being an awareness-raising tool to engaging more actively with a wider variety of stakeholders in workshops, training over 1000 children in Latin America. Its contents were also translated into English as a first step in distributing this educational model to other countries and contexts. Through joint work between ReAct&#x2019;s regional nodes, the Alforja is being adapted to Kenyan context. ReAct is also training the next generation of future leaders in AMR, from school clubs in India to Innovate4AMR, a global student design competition co-organized with the International Federation of Medical Students&#x2019; Associations and the WHO.&#xA0;ReAct&#xA0; has expanded their &#xA0;reach of support through targeted materials and their open-access online repository, the ReAct Toolbox, sharing reliable information, guidance and tools to support action on ABR especially for LMIC users. In 2018, more than 70,000 users from over 150 countries accessed the Toolbox, and it had more than 8000 returning users.&#xA0;
In this period, ReAct has evolved a lot as a network. This has occurred through improvements&#xA0;in internal processes concerning staffing, communication, financial management, monitoring &amp; evaluation and planning. This has occurred at the same time as interest and action on antibiotic resistance have reached unprecedented levels, which also means that ReAct has had to adapt to ever-increasing requests for its expertise. ReAct has proactively engaged with governments and funders to increase funding for action on ABR, including co-hosting a meeting and publishing a report on AMR financing in 2018. ReAct also continued to pursue both potential core funding and project-based funding, and has successfully raised approximately 11.9 million SEK, in addition to the core grant from Sida. 
By insisting on the combination of ensuring a strong evidence-base for its work, a high level of&#xA0;technical and scientific expertise and by focusing on the development of sustainable solutions for LMICs, ReAct fills a critical niche, even in an increasingly crowded field of actors. A continuous challenge is the workload as the field of ABR moves at record-breaking speed, with new opportunities (and threats) surfacing almost every week. Responding to these changes in a dynamic manner has been a hallmark of ReAct, and also part of their success. An example is the appointment of not one, but two ReAct senior staff to the UN IACG. With ReAct&#x2019;s &#xA0;new Strategic Plan (starting in year 2019) , ReAct looks forward to sharpening their focus and prioritizing efforts in building a positive agenda grounded in scientific evidence and sound policy choices to enable greater cross-sectoral and global collective action on ABR.</narrative>
   </description>
   <indicator ascending="0" measure="5">
    <title>
     <narrative xml:lang="EN">Not applicable</narrative>
    </title>
    <description>
     <narrative xml:lang="EN">No indicator available - only a description of the activity results is published</narrative>
    </description>
   </indicator>
  </result>
  <crs-add>
   <other-flags code="2" significance="1"></other-flags>
  </crs-add>
  <contribution contributionid="61050137" xmlns="http://sida.se/ns/contribution#"></contribution>
 </iati-activity>
</iati-activities>
